Company Analysis Noile-Immune Biotech Inc.
1. Summary
Advantages
- Price (172 Β₯) is less than fair price (752.04 Β₯)
Disadvantages
- Dividends (0%) are below the sector average (2.65%).
- The stock's return over the last year (-13.85%) is lower than the sector average (-0.1164%).
- The company's current efficiency (ROE=-19.87%) is lower than the sector average (ROE=-9.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Noile-Immune Biotech Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -5.6% | -0% | -2.4% |
| 90 days | -2.3% | -0% | -5% |
| 1 year | -13.8% | -0.1% | -6.5% |
4893 vs Sector: Noile-Immune Biotech Inc. has significantly underperformed the "Healthcare" sector by -13.73% over the past year.
4893 vs Market: Noile-Immune Biotech Inc. has significantly underperformed the market by -7.38% over the past year.
Stable price: 4893 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 4893 with weekly volatility of -0.2663% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (172 Β₯) is lower than the fair price (752.04 Β₯).
Price significantly below the fair price: The current price (172 Β₯) is 337.2% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (110.39).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (129.47).
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.47) is lower than that of the sector as a whole (70.27).
P/BV vs Market: The company's P/BV (1.47) is lower than that of the market as a whole (96.37).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (26.31) is lower than that of the sector as a whole (74.99).
P/S vs Market: The company's P/S indicator (26.31) is lower than that of the market as a whole (96.35).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-3.58) is lower than that of the sector as a whole (16.85).
EV/Ebitda vs Market: The company's EV/Ebitda (-3.58) is lower than that of the market as a whole (102.89).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 5130.8% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (5130.8%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-2.05%).
5.4. ROE
ROE vs Sector: The company's ROE (-19.87%) is lower than that of the sector as a whole (-9.24%).
ROE vs Market: The company's ROE (-19.87%) is lower than that of the market as a whole (7.67%).
5.5. ROA
ROA vs Sector: The company's ROA (-19.55%) is lower than that of the sector as a whole (-9.69%).
ROA vs Market: The company's ROA (-19.55%) is lower than that of the market as a whole (3.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (9.09%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (8.77%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '2.65%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
